Windlas Biotech Analyst Review May 2026
- May 19, 2026
- Posted by: Neeraj Pandey
- Category: News
This Windlas Biotech analyst review for May 2026 covers the key data investors need for WINDLAS at its current price of Rs 730. Windlas Biotech (NSE: WINDLAS) is a pharmaceutical CDMO company with a market capitalisation of approximately Rs 1,000 crore, specialising in oral solid dosage form manufacturing for Indian pharma brands. The analyst consensus target of Rs 860 implies meaningful upside, and this Windlas Biotech analyst review examines technical levels, business segments, valuation, and key risks for WINDLAS through FY27.
Click Here – Get Free Investment Predictions
Windlas Biotech Company Snapshot May 2026
Windlas Biotech manufactures tablets, capsules, syrups, and dry syrups for branded domestic pharma companies under contract. The company’s WHO-GMP compliant facilities and formulation development capabilities serve mid-size pharma clients. The table below summarises the key data referenced in this Windlas Biotech analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | WINDLAS |
| Sector | Pharmaceuticals – CDMO |
| CMP (May 2026) | Rs 730 |
| 52 Week High | Rs 1,052 |
| 52 Week Low | Rs 690 |
| Market Cap | Rs 1,000 Crore |
| Trailing P/E | 22x |
| Analyst Consensus Target | Rs 860 |
| Bull Case Target | Rs 1,100 |
| Bear Case Target | Rs 680 |
Analyst Insight in This Windlas Biotech Analyst Review
Senior Research Analyst Ankit Jaiswal flags Windlas Biotech as a stock to watch in May 2026. At Rs 730, Ankit Jaiswal identifies key support in the Rs 704 to Rs 694 band and resistance near Rs 774. He suggests watching Windlas Biotech for a potential move toward Rs 860, subject to Pharmaceuticals – CDMO sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Windlas Biotech analyst review and does not constitute a trade recommendation.
Technical Analysis in This Windlas Biotech Analyst Review
At Rs 730, WINDLAS is trading within its 52-week band of Rs 690 to Rs 1,052. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 704 to Rs 694 band while resistance is seen in the Rs 774 to Rs 795 zone. A sustained move above Rs 774 could open the path toward the analyst consensus target of Rs 860 as outlined in this Windlas Biotech analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 704 to Rs 694 – investors tracking this Windlas Biotech analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for WINDLAS.
- Resistance Zone: Rs 774 to Rs 795 – a sustained close above Rs 774 would be a positive breakout signal worth flagging in this Windlas Biotech analyst review.
- Medium-Term Target: The analyst consensus of Rs 860 represents the base-case upside scenario in this Windlas Biotech analyst review.
Business Segment Analysis
Oral Solid Dosage CDMO (Tablets and Capsules)
This is the primary revenue and margin driver for Windlas Biotech, directly supporting the earnings trajectory toward the consensus target of Rs 860.
Syrup and Liquid Formulation Manufacturing
This segment adds scale and diversification to Windlas Biotech’s business model and is a meaningful EPS contributor through FY27 and FY28.
Nutraceutical and Specialty CDMO Services
This represents the medium-term growth frontier for Windlas Biotech and a key re-rating catalyst over the next 12 to 24 months.
Valuation in This Windlas Biotech Analyst Review
At Rs 730, Windlas Biotech trades at a trailing P/E of 22x. This Windlas Biotech analyst review presents three scenarios: a bull case of Rs 1,100 on strong earnings delivery and sector tailwinds, a base case of Rs 860 at analyst consensus, and a bear case of Rs 680 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Windlas Biotech analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 1,100 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 860 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 680 | Earnings miss or macro headwinds |
Trade Outlook for Windlas Biotech
Based on the technical and fundamental analysis in this Windlas Biotech analyst review, investors might watch WINDLAS near the support zone of Rs 704 to Rs 694 for potential opportunities. A flag above Rs 774 could suggest improving momentum toward Rs 860. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Windlas Biotech in FY27
A well-rounded Windlas Biotech analyst review must assess downside risks. Key risks for Windlas Biotech include a macro slowdown affecting Pharmaceuticals – CDMO sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in WINDLAS.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Windlas Biotech Analyst Review Verdict for 2026
This Windlas Biotech analyst review concludes that at Rs 730, WINDLAS offers a defined risk-reward with a consensus target of Rs 860. The 52-week range of Rs 690 to Rs 1,052 provides context on the current entry point. Use this Windlas Biotech analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on WINDLAS.
Frequently Asked Questions: Windlas Biotech Analyst Review 2026
What is the analyst target for Windlas Biotech in 2026?
The analyst consensus target is Rs 860, with a bull case of Rs 1,100 and a bear case of Rs 680. This Windlas Biotech analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Windlas Biotech a good investment at Rs 730?
At Rs 730 with a P/E of 22x and a consensus target of Rs 860, this Windlas Biotech analyst review is constructive for medium to long-term investors in the Pharmaceuticals – CDMO sector. Always consult a SEBI-registered advisor before investing.
What is Windlas Biotech’s 52-week high and low?
The 52-week high is Rs 1,052 and the 52-week low is Rs 690. At Rs 730, WINDLAS is positioned within this range as detailed in this Windlas Biotech analyst review.
What are the key risks for Windlas Biotech?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – CDMO sector, all assessed in this Windlas Biotech analyst review.
Where can I track live data for Windlas Biotech?
Track Windlas Biotech’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Windlas Biotech analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
